Cancer research
GLP-1 Weight-Loss Drugs May Help Lower Cancer Risk Beyond Weight Loss
A recent study found that the first-generation GLP-1 weight-loss drugs, liraglutide (Saxenda) and exenatide (Byetta), were associated with a 41% lower risk of obesity-related cancers compared to weight-loss surgery. Researchers believe that the GLP-1 drugs' ability to reduce inflammation and other mechanisms may contribute to their cancer-fighting benefits. Key